Skip to main content

Table 1 Intogen significantly enriched pathways

From: Complete response to neoadjuvant chemoradiotherapy in rectal cancer is associated with RAS/AKT mutations and high tumour mutational burden

ID

Pathway

Z score

p value

Q value

hsa05210

Colorectal cancer

8.14

1.88E−16

1.62E−14

hsa05222

Small cell lung cancer

6.73

8.43E−12

3.63E−10

hsa04150

mTOR signalling pathway

6.10

4.99E−10

1.43E−08

hsa04310

Wnt signalling pathway

5.96

1.26E−09

2.71E−08

hsa05212

Pancreatic cancer

5.77

3.91E−09

6.60E−08

hsa00562

Inositol phosphate metabolism

5.71

5.37E−09

6.60E−08

hsa04070

Phosphatidylinositol signalling system

5.71

5.37E−09

6.60E−08

hsa04115

p53 signalling pathway

5.60

1.01E−08

1.09E−07

hsa05166

Human T-cell leukemia virus 1 infection

5.50

1.87E−08

1.79E−07

hsa05169

Epstein-Barr virus infection

4.99

2.96E−07

2.12E−06

hsa05162

Measles

4.99

2.96E−07

2.12E−06

hsa04210

Apoptosis

4.99

2.96E−07

2.12E−06

hsa05217

Basal cell carcinoma

4.66

1.56E−06

1.03E−05

hsa04120

Ubiquitin mediated proteolysis

4.59

2.16E−06

1.33E−05